Information for Patients: Patients should use NASAREL at regular intervals since its effectiveness depends on its regular use. Patients should take the medication as directed and should not exceed the prescribed dose. A decrease in symptoms can be expected to occur within a few days of initiating therapy in allergic rhinitis patients. Patients should contact their physician if the condition worsens, if sneezing or nasal irritation occurs, or if symptoms do not improve by 3 weeks.
Persons taking immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or measles . Patients should also be advised that if they are exposed, medical advice should be sought without delay.
For proper use of this unit and to attain maximum improvement, the patient should read and follow the accompanying Patient Instructions carefully.
In a pharmacokinetic study comparing flunisolide nasal solution (flunisolide nasal spray .025%) (29 mcg per spray) with flunisolide nasal solution (flunisolide nasal spray .025%) (25 mcg per spray), the original formulation, the two formulations were not bioequivalent. The total absorption of flunisolide nasal solution (29 mcg per spray) was 25% less than that of flunisolide nasal solution (25 mcg per spray), and the peak plasma concentration was 30% lower. The clinical significance of these differences is likely to be small, particularly since clinical efficacy is attributable to a local effect on nasal mucosa (see Pharmacodynamics ).
Elimination: The elimination rate of intravenous administered fluticasone propionate is linear over the 250-1000mcg dose range and are characterized by a high plasma clearance (CL=/min). Peak plasma concentrations are reduced by approximately 98% within 3-4 hours and only low plasma concentrations were associated with the terminal half-life. The renal clearance of fluticasone propionate is negligible (<%) and less than 5% as the carboxylic acid metabolite. The major route of elimination is the excretion of fluticasone propionate and its metabolites in the bile.